Literature DB >> 32356320

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.

Nicholas J Short1, Guillaume Richard-Carpentier1, Rashmi Kanagal-Shamanna2, Keyur P Patel2, Marina Konopleva1, Ioannis Papageorgiou3, Naveen Pemmaraju1, Gautam Borthakur1, Farhad Ravandi1, Courtney D DiNardo1, Tapan M Kadia1, Hagop Kantarjian1, Jatinder K Lamba3, Naval Daver1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32356320     DOI： 10.1002/ajh.25854

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

Review 1.  Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.

Authors:  Juan Eduardo Megías-Vericat; David Martínez-Cuadrón; Antonio Solana-Altabella; José Luis Poveda; Pau Montesinos
Journal:  Pharmaceutics       Date:  2022-04-17       Impact factor: 6.525

2.  No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Authors:  Tamara Castaño-Bonilla; Eva Barragán; Claudia Sargas; Alejandro Sanz; Lorenzo Algarra; Pilar Herrera-Puente; Raimundo García-Boyero; Manuel Barrios; David Martinez-Cuadron; Rebeca Rodriguez-Veiga; Blanca Boluda; Cristina Gil; Josefina Serrano-López; Joaquín Martínez-López; María José Sayas-Lloris; María Teresa Olave; Rosalía Riaza-Grau; Teresa Bernal-Del Castillo; María José Larrayoz; Raquel Amigo; Antonio Jiménez-Velasco; Joaquín Sánchez; Rosa Ayala; Carlos Blas; Daniel Lainez; Juana Serrano-López; Miguel A Sanz; Juan M Alonso-Domínguez; Pau Montesinos
Journal:  Dis Markers       Date:  2022-08-23       Impact factor: 3.464

3.  Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin.

Authors:  Katrin Teich; Julia Krzykalla; Silke Kapp-Schwoerer; Verena I Gaidzik; Richard F Schlenk; Peter Paschka; Daniela Weber; Walter Fiedler; Michael W M Kühn; Thomas Schroeder; Karin Mayer; Michael Lübbert; Dhanya Ramachandran; Axel Benner; Arnold Ganser; Hartmut Döhner; Michael Heuser; Konstanze Döhner; Felicitas Thol
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941

4.  Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.

Authors:  Jatinder K Lamba; Soheil Meshinchi
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.